WO2008004001A3 - The use of pvp to control the release profile of an active ingredient from a hydrophilic polymer matrix tablet - Google Patents

The use of pvp to control the release profile of an active ingredient from a hydrophilic polymer matrix tablet Download PDF

Info

Publication number
WO2008004001A3
WO2008004001A3 PCT/GB2007/050375 GB2007050375W WO2008004001A3 WO 2008004001 A3 WO2008004001 A3 WO 2008004001A3 GB 2007050375 W GB2007050375 W GB 2007050375W WO 2008004001 A3 WO2008004001 A3 WO 2008004001A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydrophilic polymer
polymer matrix
pvp
active ingredient
control
Prior art date
Application number
PCT/GB2007/050375
Other languages
French (fr)
Other versions
WO2008004001A2 (en
Inventor
Ian Hardy
Shaun Fitzpatrick
Tolulope Ajayi
Anne Windberg-Baarup
Gareth Chadwick
Claudia Neri
Paul Vincent Byway
Original Assignee
Merck Sharp & Dohme
Ian Hardy
Shaun Fitzpatrick
Tolulope Ajayi
Anne Windberg-Baarup
Gareth Chadwick
Claudia Neri
Paul Vincent Byway
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Ian Hardy, Shaun Fitzpatrick, Tolulope Ajayi, Anne Windberg-Baarup, Gareth Chadwick, Claudia Neri, Paul Vincent Byway filed Critical Merck Sharp & Dohme
Publication of WO2008004001A2 publication Critical patent/WO2008004001A2/en
Publication of WO2008004001A3 publication Critical patent/WO2008004001A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Abstract

The invention relates to the use of polyvinyl pyrrolidone (PVP) for the modulation of drug release kinetics from hydrophilic polymer matrix tablets, in particular hydroxypropyl methyl cellulose (HPMC) matrix tablets. Another aspect of the invention is a method of drug release from a hydrophilic polymer matrix tablet, for example a hydroxypropyl methyl cellulose (HPMC) and compositions thereof.
PCT/GB2007/050375 2006-07-05 2007-07-04 The use of pvp to control the release profile of an active ingredient from a hydrophilic polymer matrix tablet WO2008004001A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0613310.2 2006-07-05
GB0613310A GB0613310D0 (en) 2006-07-05 2006-07-05 The use of pvp to control the release profile of an active ingredient from a hydrophilic polymer matrix tablet

Publications (2)

Publication Number Publication Date
WO2008004001A2 WO2008004001A2 (en) 2008-01-10
WO2008004001A3 true WO2008004001A3 (en) 2008-03-27

Family

ID=36926461

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/050375 WO2008004001A2 (en) 2006-07-05 2007-07-04 The use of pvp to control the release profile of an active ingredient from a hydrophilic polymer matrix tablet

Country Status (2)

Country Link
GB (1) GB0613310D0 (en)
WO (1) WO2008004001A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200082006A (en) * 2018-12-28 2020-07-08 주식회사 대웅제약 Extended release formulation containing tofacitinib or pharmaceutically acceptable salts thereof as an active ingredient and the preparation method for the same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067905A1 (en) * 2001-02-27 2002-09-06 Kos Pharmaceuticals, Inc. A sustained release pharmaceutical formulation
US20030157153A1 (en) * 1997-03-06 2003-08-21 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
WO2003103634A1 (en) * 2002-06-07 2003-12-18 Ranbaxy Laboratories Limited Sustained release oral dosage forms of gabapentin
WO2004071374A2 (en) * 2003-02-11 2004-08-26 Torrent Pharmaceuticals Limited Once a day orally administered pharmaceutical compositions
WO2005016319A2 (en) * 2003-08-06 2005-02-24 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157153A1 (en) * 1997-03-06 2003-08-21 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
WO2002067905A1 (en) * 2001-02-27 2002-09-06 Kos Pharmaceuticals, Inc. A sustained release pharmaceutical formulation
WO2003103634A1 (en) * 2002-06-07 2003-12-18 Ranbaxy Laboratories Limited Sustained release oral dosage forms of gabapentin
WO2004071374A2 (en) * 2003-02-11 2004-08-26 Torrent Pharmaceuticals Limited Once a day orally administered pharmaceutical compositions
WO2005016319A2 (en) * 2003-08-06 2005-02-24 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CONTE U ET AL: "Modulation of the dissolution profiles from Geomatrix@? multi-layer matrix tablets containing drugs of different solubility", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 17, no. 9, May 1996 (1996-05-01), pages 889 - 896, XP004032726, ISSN: 0142-9612 *
HARDY ET AL: "Modulation of drug release kinetics from hydroxypropyl methyl cellulose matrix tablets using polyvinyl pyrrolidone", INTERNATIONAL JOURNAL OF PHARMACEUTICS, AMSTERDAM, NL, vol. 337, no. 1-2, 19 May 2007 (2007-05-19), pages 246 - 253, XP022085275, ISSN: 0378-5173 *

Also Published As

Publication number Publication date
WO2008004001A2 (en) 2008-01-10
GB0613310D0 (en) 2006-08-16

Similar Documents

Publication Publication Date Title
WO2009108077A3 (en) Pharmaceutical composition for poorly soluble drugs
WO2007036952A3 (en) Novel sustained release dosage form
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
WO2004112756A8 (en) Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
WO2006135723A3 (en) Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
WO2003066030A3 (en) Pharmaceutical tablet
WO2009058950A3 (en) Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
EP2286801A3 (en) Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
WO2007052125A3 (en) Solid oral pharmaceutical compositions for once daily dosing containing pregabalin, a matrix forming agent and a swelling agent
WO2005011636A3 (en) Spray drying processes for forming solid amorphous dispersions of drugs and polymers
DK2032123T3 (en) Use of a hydrophilic matrix containing a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for the treatment of female STDs
JP2009532389A5 (en)
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
WO2010006143A3 (en) Transdermal estrogen device and delivery
WO2010103365A3 (en) Sustained release composition of therapeutic agent
MY130332A (en) Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer
WO2009001099A3 (en) A pharmaceutical composition comprising polyaphron dispersion
WO2005123045A3 (en) Controlled release matrix pharmaceutical dosage formulation
WO2010026467A3 (en) Controlled release tablet of a highly water soluble active agent such as levetiracetam, or citicoline
MX2009008197A (en) Extended-release dosage form.
WO2008039351A3 (en) Method of manufacturing tablets containing pharmacologically active agents
WO2008004001A3 (en) The use of pvp to control the release profile of an active ingredient from a hydrophilic polymer matrix tablet
WO2003086362A3 (en) Method of stabilizing bupropion hydrochloride tablets
TNSN08094A1 (en) Photostable pharmaceutical composition containing brivudine for the treatment of herpetic keratitis
WO2010018175A3 (en) Oral pharmaceutical formulation for omeprazole comprising a specific separation layer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07733796

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07733796

Country of ref document: EP

Kind code of ref document: A2